Strategy for effective brain drug delivery.
暂无分享,去创建一个
Javed Ali | Sarwar Beg | Kanchan Kohli | Sanjula Baboota | Alka Ahuja | S. Baboota | J. Ali | S. Beg | A. Samad | K. Kohli | M Intakhab Alam | Abdus Samad | M Akbar | A. Ahuja | M. I. Alam | M. Akbar
[1] Sur Sharma,et al. Advances in antibody-directed enzyme prodrug therapy. , 2005, Current opinion in investigational drugs.
[2] A. Misra,et al. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting , 2008, Journal of drug targeting.
[3] F. Girardin. Membrane transporter proteins: a challenge for CNS drug development , 2006, Dialogues in clinical neuroscience.
[4] Rakesh K. Sharma,et al. Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels , 2006, Journal of drug targeting.
[5] Y. Olsson,et al. Observations on exsudation of fibronectin, fibrinogen and albumin in the brain after carotid infusion of hyperosmolar solutions , 2004, Acta Neuropathologica.
[6] J. Jankovic,et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.
[7] K. Hynynen,et al. Use of ultrasound pulses combined with Definity for targeted blood-brain barrier disruption: a feasibility study. , 2007, Ultrasound in Medicine and Biology.
[8] E. Kohmura,et al. Basic Fibroblast Growth Factor Prevents Thalamic Degeneration after Cortical Infarction , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[9] D. Ben-Nathan,et al. Sodium dodecylsulphate induces a breach in the blood-brain barrier and enables a West Nile virus variant to penetrate into mouse brain , 1989, Brain Research.
[10] E. Unger,et al. Therapeutic applications of lipid-coated microbubbles. , 2004, Advanced drug delivery reviews.
[11] R. Bartus,et al. The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain Barrier , 2001, Clinical pharmacokinetics.
[12] B. Engelhardt,et al. The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction , 2009, Seminars in Immunopathology.
[13] D. A. Kharkevich,et al. [Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles]. , 1996, Eksperimental'naia i klinicheskaia farmakologiia.
[14] A. Babbar,et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. , 2008, International journal of pharmaceutics.
[15] Xin-guo Jiang,et al. The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats , 2006, Journal of drug targeting.
[16] P. Low,et al. Folate-mediated targeting of therapeutic and imaging agents to cancers. , 1998, Critical reviews in therapeutic drug carrier systems.
[17] J. Poupaert,et al. A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)prop anoyl] propane-1,2,3-triol. , 1986, Journal of medicinal chemistry.
[18] Xing Tang,et al. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[19] Y. Olsson,et al. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. , 1988, Acta neuropathologica.
[20] F. Heppner,et al. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion , 2003, Nature.
[21] M A Vandelli,et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[22] J. Herms,et al. Intracarotid administration of short‐chain alkylglycerols for increased delivery of methotrexate to the rat brain , 2003, British journal of pharmacology.
[23] U. Bickel,et al. Delivery of peptides and proteins through the blood-brain barrier. , 1993 .
[24] K. Geiger,et al. Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles , 2004, International journal of cancer.
[25] H. Wiśniewski,et al. Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier , 1995, Journal of neurocytology.
[26] Francis C Szoka,et al. Barriers to carrier mediated drug and gene delivery to brain tumors. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[27] Tushar K. Vyas,et al. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. , 2008, International journal of pharmaceutics.
[28] T. Kundu,et al. Intrinsically fluorescent carbon nanospheres as a nuclear targeting vector: delivery of membrane-impermeable molecule to modulate gene expression in vivo. , 2008, Nano letters.
[29] Buchwald,et al. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. , 1999, Advanced drug delivery reviews.
[30] W. Mark Saltzman,et al. Chemotherapeutic Drugs Released from Polymers: Distribution of 1,3-bis(2-chloroethyl)-l-nitrosourea in the Rat Brain , 1996, Pharmaceutical Research.
[31] M. Brewster,et al. The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems. , 2002, Die Pharmazie.
[32] W. Löscher,et al. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family , 2011, NeuroRX.
[33] W. Pardridge,et al. Drug and Gene Delivery to the Brain The Vascular Route , 2002, Neuron.
[34] W. Pardridge. Brain drug targeting and gene technologies. , 2001, Japanese journal of pharmacology.
[35] J. Dean,et al. The Safety, Tolerability, and Pharmacokinetics of Fosphenytoin after Intramuscular and Intravenous Administration in Neurosurgery Patients , 1996, Pharmacotherapy.
[36] Vanessa S. Rothholtz,et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration , 2000, Brain Research.
[37] Aaron P. Campbell,et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[38] W. Saltzman,et al. Pharmacokinetics of the Carmustine Implant , 2002, Clinical pharmacokinetics.
[39] Jie Ren,et al. Preparation and Therapeutic Efficacy of Polysorbate-80-Coated Amphotericin B/PLA-b-PEG Nanoparticles , 2009, Journal of biomaterials science. Polymer edition.
[40] E. Chiocca,et al. Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. , 1999, Human gene therapy.
[41] E. Neuwelt,et al. An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. , 2005, AJNR. American journal of neuroradiology.
[42] Jie Pan,et al. Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. , 2008, Biomaterials.
[43] M. Samanta,et al. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[44] R. Sharma,et al. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[45] R. Kim,et al. Blood−brain barrier transporters and response to CNS-active drugs , 2009, European Journal of Clinical Pharmacology.
[46] N. Savaraj,et al. Pharmacology of intrathecal VP-16-213 in dogs , 1992, Journal of Neuro-Oncology.
[47] R. Brakenhoff,et al. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. , 1998, Blood.
[48] Qing Wang,et al. Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia. , 2007, Frontiers in bioscience : a journal and virtual library.
[49] E. Björk,et al. Direct Nose-to-Brain Transfer of Morphine After Nasal Administration to Rats , 2006, Pharmaceutical Research.
[50] A. Dalpiaz,et al. Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach , 2008, Molecules.
[51] K. Waku,et al. 2-Arachidonoylglycerol and anandamide oppositely modulate norepinephrine release from the rat heart sympathetic nerves. , 2001, Japanese journal of pharmacology.
[52] Y. Cai,et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[53] Keith L Black,et al. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. , 2004, Cancer control : journal of the Moffitt Cancer Center.
[54] D. Geschwind,et al. Disruption of Astrocyte STAT3 Signaling Decreases Mitochondrial Function and Increases Oxidative Stress In Vitro , 2010, PloS one.
[55] Lei Zhang,et al. Gum Arabic-Coated Magnetic Nanoparticles for Potential Application in Simultaneous Magnetic Targeting and Tumor Imaging , 2009, The AAPS Journal.
[56] Targeting drugs to the brain by redox chemical delivery systems , 2000, Medicinal research reviews.
[57] W. Pardridge. Vector-mediated peptide drug delivery to the brain. , 1995, Advanced drug delivery reviews.
[58] Bhavna,et al. Potential of nanoparticulate drug delivery systems by intranasal administration. , 2010, Current pharmaceutical design.
[59] J. M. Beals,et al. Assembly and Dissociation of Human Insulin and LysB28ProB29-Insulin Hexamers: A Comparison Study , 2004, Pharmaceutical Research.
[60] W. Pardridge,et al. Human Insulin Receptor Monoclonal Antibody Undergoes High Affinity Binding to Human Brain Capillaries in Vitro and Rapid Transcytosis Through the Blood–Brain Barrier in Vivo in the Primate , 1995, Pharmaceutical Research.
[61] W. Pardridge,et al. Human blood-brain barrier insulin-like growth factor receptor. , 1988, Metabolism: clinical and experimental.
[62] J. Kreuter,et al. Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.
[63] D. A. Kharkevich,et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.
[64] H. Steinbusch,et al. Delivery of peptide and protein drugs over the blood–brain barrier , 2009, Progress in Neurobiology.
[65] R. Sherwood,et al. Antibody-enzyme conjugates for cancer therapy. , 1996, Journal of the National Cancer Institute.
[66] Gary M Pollack,et al. Nasal drug administration: potential for targeted central nervous system delivery. , 2005, Journal of pharmaceutical sciences.
[67] J. Benoit,et al. Development of microspheres for neurological disorders: from basics to clinical applications. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[68] M. Lakomek,et al. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats , 2002, Cancer Chemotherapy and Pharmacology.
[69] R. Müller,et al. The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis , 2009, Journal of drug targeting.
[70] A. Samad,et al. Liposomal drug delivery systems: an update review. , 2007, Current drug delivery.
[71] Kullervo Hynynen,et al. Ultrasound for drug and gene delivery to the brain. , 2008, Advanced drug delivery reviews.
[72] Kinam Park. Transport across the blood-brain barrier using albumin nanoparticles. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[73] R. Spooner,et al. Genetic delivery of enzymes for cancer therapy. , 1995, Gene therapy.
[74] N. Bodor,et al. Facile, One-Step Preparation of Trigonellinate Esters , 1987 .
[75] H. Wakimoto,et al. Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors , 2002, Cancer Gene Therapy.
[76] Xin-guo Jiang,et al. From nose to brain: understanding transport capacity and transport rate of drugs , 2008, Expert opinion on drug delivery.
[77] L. Illum. Transport of drugs from the nasal cavity to the central nervous system. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[78] F. Balis,et al. Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Temozolomide in Non-human Primates , 2003, Journal of Neuro-Oncology.
[79] W. Pardridge,et al. Brain-specific expression of an exogenous gene after i.v. administration , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[80] S. Sheleg,et al. Local Chemotherapy with Cisplatin-depot for Glioblastoma Multiforme , 2002, Journal of Neuro-Oncology.
[81] G. T. Cottrell,et al. Sensory circumventricular organs: central roles in integrated autonomic regulation , 2004, Regulatory Peptides.
[82] J. Lawrenson,et al. Pericytes: Cell Biology and Pathology , 2001, Cells Tissues Organs.
[83] H. Brem,et al. Biodegradable polymer implants to treat brain tumors. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[84] B. Sabel,et al. Nanoparticle technology for delivery of drugs across the blood-brain barrier. , 1998, Journal of pharmaceutical sciences.
[85] J. Ghersi-Egea,et al. The Role of the Choroid Plexus in Neutrophil Invasion after Traumatic Brain Injury , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[86] Tushar K. Vyas,et al. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. , 2008, Journal of pharmaceutical sciences.
[87] M. Bally,et al. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo , 2004, Cancer Chemotherapy and Pharmacology.
[88] N. Zhang,et al. Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. , 2008, International journal of pharmaceutics.
[89] J M Scherrmann,et al. Drug delivery to brain via the blood-brain barrier. , 2002, Vascular pharmacology.
[90] H. Gendelman,et al. Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS1 , 2009, The Journal of Immunology.
[91] E. Brittebo,et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[92] A. Carpentier. Neuro-oncology: the growing role of chemotherapy in glioma , 2005, The Lancet Neurology.
[93] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.
[94] A. Lackner,et al. Simian immunodeficiency virus disrupts extended lengths of the blood–brain barrier , 2005, Journal of medical primatology.
[95] D. Kopacz,et al. Extended-Duration Analgesia: Update on Microspheres and Liposomes , 2005, Regional Anesthesia & Pain Medicine.
[96] T. Stockley,et al. The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. , 1999, Trends in biotechnology.
[97] Andrew Baird,et al. Enhanced Prospects for Drug Delivery and Brain Targeting by the Choroid Plexus–CSF Route , 2005, Pharmaceutical Research.
[98] D. A. Kharkevich,et al. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles , 1995 .
[99] G. Amidon,et al. Peptide-based Drug Design, Controlling Transport and Metabolism , 1995 .
[100] W. Saltzman,et al. Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders. , 1996, Journal of pharmaceutical sciences.
[101] D. A. Kharkevich,et al. Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.
[102] Alexander V Kabanov,et al. Nanogels for oligonucleotide delivery to the brain. , 2004, Bioconjugate chemistry.
[103] Thomas Wirth,et al. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[104] Xun Sun,et al. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[105] T Sinkjaer,et al. Interfacing the body's own sensing receptors into neural prosthesis devices. , 1999, Technology and health care : official journal of the European Society for Engineering and Medicine.
[106] E. Barbu,et al. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood–brain barrier , 2009 .
[107] D. Crommelin,et al. A new application for liposomes in cancer therapy , 1993, FEBS letters.
[108] D. Tzemach,et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals , 1997 .
[109] Stanley B. Prusiner,et al. Nobel Lecture: Prions , 1998 .
[110] G. Tosi,et al. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. , 2009, Nanomedicine : nanotechnology, biology, and medicine.
[111] J. Gomori,et al. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood‐brain barrier disruption in patients with brain lymphoma , 2000, Clinical pharmacology and therapeutics.
[112] Theresa M. Allen,et al. Pharmacokinetics of long-circulating liposomes , 1995 .
[113] W. Banks,et al. Delivery of Galanin-Like Peptide to the Brain: Targeting with Intranasal Delivery and Cyclodextrins , 2008, Journal of Pharmacology and Experimental Therapeutics.
[114] R. Egleton,et al. Development of neuropeptide drugs that cross the blood-brain barrier , 2011, NeuroRX.
[115] R. Puri,et al. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. , 2004, Journal of neurosurgery.
[116] W. Pardridge. Blood-brain barrier drug targeting: the future of brain drug development. , 2003, Molecular interventions.
[117] P. Kennedy,et al. Restoration of neural output from a paralyzed patient by a direct brain connection , 1998, Neuroreport.
[118] Lisbeth Illum,et al. Nanoparticles for direct nose-to-brain delivery of drugs. , 2009, International journal of pharmaceutics.
[119] E. De Clercq,et al. Targeting of antiviral drugs to T4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro. , 1990, Biochemical pharmacology.
[120] W. Frey,et al. Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury. , 2007, Frontiers in bioscience : a journal and virtual library.
[121] C. Crone,et al. Electrical resistance of a capillary endothelium , 1981, The Journal of general physiology.
[122] A. Ommaya. Implantable devices for chronic access and drug delivery to the central nervous system. , 1984, Cancer drug delivery.
[123] J. Pandit,et al. Controlled release formulations in neurology practice , 2006 .
[124] D. Murry,et al. Clinical Pharmacology of Encapsulated Sustained-Release Cytarabine , 2000, The Annals of pharmacotherapy.
[125] W. Pardridge,et al. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[126] W. Pardridge,et al. Blood-brain barrier delivery. , 2007, Drug discovery today.
[127] B. Swartz,et al. The Human Brain GLUT1 Glucose Transporter: Ultrastructural Localization to the Blood—Brain Barrier Endothelia , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[128] E. Brittebo,et al. Transfer of Dopamine in the Olfactory Pathway Following Nasal Administration in Mice , 2000, Pharmaceutical Research.
[129] C. Borlongan,et al. Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport , 2003, Brain Research Bulletin.
[130] K. Frei,et al. Molecular and cellular permeability control at the blood–brain barrier , 2001, Brain Research Reviews.
[131] Shailendra Joshi,et al. Enhanced Disruption of the Blood Brain Barrier by Intracarotid Mannitol Injection During Transient Cerebral Hypoperfusion in Rabbits , 2007, Journal of neurosurgical anesthesiology.
[132] Alexander Sasha Rabchevsky,et al. Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood–brain barrier without inducing reactive gliosis , 1999, Brain Research.
[133] Paul R. Lockman,et al. Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability , 2004, Journal of drug targeting.
[134] S. Schwarze,et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.
[135] James L. Frazier,et al. Local drug delivery to the brain. , 2002, Advanced drug delivery reviews.
[136] W. Pardridge,et al. A Direct In Vitro Demonstration of Insulin Binding to Isolated Brain Microvessels , 1981, Diabetes.
[137] D. Begley. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.
[138] P. Yeole,et al. Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats , 2009, The Journal of pharmacy and pharmacology.
[139] W. Pardridge,et al. Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin , 2001, Brain Research.
[140] Y. Kanai,et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. , 2002, Molecular pharmacology.
[141] W. Pardridge,et al. Blood—Brain Barrier Genomics , 2001, Methods in molecular medicine.
[142] K Hynynen,et al. Histologic effects of high intensity pulsed ultrasound exposure with subharmonic emission in rabbit brain in vivo. , 1995, Ultrasound in medicine & biology.
[143] W. Pardridge. The blood-brain barrier and neurotherapeutics , 2011, NeuroRX.
[144] S. Olesen,et al. Electrical resistance of brain microvascular endothelium , 1982, Brain Research.
[145] W. Pardridge,et al. Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. , 1999, Bioconjugate chemistry.
[146] R. Sharma,et al. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan , 2006, AAPS PharmSciTech.
[147] Jarkko Rautioa,et al. Drug delivery systems for brain tumor therapy. , 2004, Current pharmaceutical design.
[148] W. Risau. Differentiation of endothelium , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[149] G. Vassal,et al. Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor Targeting , 2002, Journal of Pharmacology and Experimental Therapeutics.
[150] T. Davis,et al. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.
[151] B. Zlokovic,et al. Differential expression of Na,K-ATPase alpha and beta subunit isoforms at the blood-brain barrier and the choroid plexus. , 1993, The Journal of biological chemistry.
[152] A. Tsuji. Influx transporters and drug targeting: Application of peptide and cation transporters , 2005 .
[153] S. Davis,et al. The organ uptake of intravenously administered colloidal particles can be altered using a non‐ionic surfactant (Poloxamer 338) , 1984, FEBS letters.
[154] E. Lo,et al. Drug delivery to damaged brain , 2001, Brain Research Reviews.
[155] L. Illum,et al. Intranasal delivery: physicochemical and therapeutic aspects. , 2007, International journal of pharmaceutics.
[156] C. Springer,et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[157] F. Szoka,et al. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating , 2005, Brain Research.
[158] T. Terasaki,et al. Drug delivery to the brain utilizing blood-brain barrier transport systems , 1994 .
[159] A. Małecki,et al. Physiology and pharmacological role of the blood-brain barrier. , 2008, Pharmacological reports : PR.
[160] W. Pardridge,et al. Global non-viral gene transfer to the primate brain following intravenous administration. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[161] J. Huwyler,et al. Drug transport to brain with targeted liposomes , 2011, NeuroRX.
[162] R. Egleton,et al. Bioavailability and Transport of Peptides and Peptide Drugs into the Brain , 1997, Peptides.
[163] S. Rapoport. Osmotic Opening of the Blood–Brain Barrier: Principles, Mechanism, and Therapeutic Applications , 2000, Cellular and Molecular Neurobiology.
[164] G. Hocking,et al. Intrathecal drug spread. , 2004, British journal of anaesthesia.
[165] M. Hashida,et al. The effect of polysorbate 80 on brain uptake and analgesic effect of D-kyotorphin , 1989 .
[166] M. McGirt,et al. Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience , 2008, Annals of Surgical Oncology.
[167] C. Nicholson,et al. Extracellular space structure revealed by diffusion analysis , 1998, Trends in Neurosciences.
[168] A. Sigal,et al. Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis , 2009, Journal of Neuroimmunology.
[169] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[170] W. Pardridge,et al. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. , 1999, Cancer research.
[171] P. Senter. Activation of prodrugs by antibody‐enzyme conjugates: a new approach to cancer therapy , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[172] K. Fritze,et al. Effect of global system for mobile communication (GSM) microwave exposure on blood-brain barrier permeability in rat , 1997, Acta Neuropathologica.
[173] K. Hynynen,et al. MRI investigation of the threshold for thermally induced blood–brain barrier disruption and brain tissue damage in the rabbit brain , 2004, Magnetic resonance in medicine.
[174] I. Rubinstein,et al. Role of nanotechnology in targeted drug delivery and imaging: a concise review. , 2005, Nanomedicine : nanotechnology, biology, and medicine.